MSTX
Mast Therapeutics, Inc.NYSEMKT
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Dec. 6, 10:15 AM
    • The first patient has been enrolled in a Phase 2 clinical trial, INABLE-TRAINING, assessing Mast Therapeutics' (MSTX -2.4%) AIR001 (sodium nitrite solution for intermittent inhalation) for the treatment of heart failure patients with preserved ejection fraction. The 68-subject study will randomize participants to receive either AIR001 or placebo inhalation solution through 12 weeks of cardiac rehabilitation. The primary endpoint is the change in exercise capacity as measured by peak oxygen consumption.
    • Nitrite is a vasodilator. It is recycled in the body to form nitric oxide (NO). Nitrite-mediated NO dilates blood vessels and reduces inflammation and unwanted cell growth.
    | Tue, Dec. 6, 10:15 AM | 5 Comments
  • Mon, Nov. 21, 11:26 AM
    • Mast Therapeutics (MSTX +16.2%) reports that its evaluation of strategic alternatives includes a possible reverse merger with a privately-held firm. It says it has received several written indications of interest from companies with synergistic clinical-stage product candidates.
    • It is also exploring ways to monetize ifs vepoloxamer assets, including licensing deals.
    • Shares cratered in September after vepoloxamer flunked a late-stage study in sickle cell disease.
    | Mon, Nov. 21, 11:26 AM | 25 Comments
  • Tue, Nov. 8, 1:24 PM
    • Mast Therapeutics (NYSEMKT:MSTX): Q3 EPS of -$0.04 beats by $0.01.
    | Tue, Nov. 8, 1:24 PM
  • Tue, Nov. 8, 9:06 AM
    • Mast Therapeutics (NYSEMKT:MSTX): Q3 EPS of -$0.04 beats by $0.01.
    • Revenue of $0.05M
    • Press Release
    | Tue, Nov. 8, 9:06 AM
  • Thu, Nov. 3, 10:41 AM
    • Nano cap Mast Therapeutics (MSTX +6%) perks up on average volume in response to its announcement of encouraging preliminary results from an open-label Phase 2 clinical trial assessing now-lead product candidate AIR001 for the treatment of pulmonary hypertension (PH). The data were published in the Journal of Clinical Investigation.
    • Interim data from 36 patients receiving AIR001 (sodium nitrite solution for intermittent inhalation) showed decreases in pulmonary, right atrial and pulmonary capillary wedge pressures. The company says the effects were most pronounced in patients with PH associated with heart failure with preserved ejection fraction (PH-HFpEF). It adds that this subgroup also showed the largest increase in pulmonary artery compliance.
    • AIR001 was well-tolerated with no significant safety signals. There were also no significant decreases in peripheral oxygen saturation nor increases in methemoglobin levels about the stopping criteria of 5%.
    • Nitrite is a vasodilator. It is recycled in the body to form nitric oxide (NO). Nitrite-mediated NO dilates blood vessels and reduces inflammation and unwanted cell growth.
    | Thu, Nov. 3, 10:41 AM | 2 Comments
  • Mon, Sep. 26, 11:38 AM
    • Mast Therapeutics (MSTX -1.8%), still smarting from last week's massive haircut to its valuation after vepoloxamer failed a Phase 3 study, announces that it will wind down the development of the once-promising drug and focus its development activities on AIR001 (sodium nitrite solution for intermittent inhalation) for the treatment of heart failure with preserved ejection fraction (HFpEF). Three ongoing Phase 2 studies, two in HFpEF and one in pulmonary hypertension, will continue as planned.
    • The company says the vepoloxamer wind-down will reduce its operating expenses ~70%, from $32M - 34M down to $9M - 10M. It will also make the $10M prepayment on its outstanding loan that was triggered by the failure of the Phase 3.
    • AIR001, obtained via its acquisition of Aires Pharmaceuticals in February, is a direct vasodilator that is recycled in vivo to form nitric oxide independent of the classical nitric oxide synthase pathway. In a Phase 2a study, HFpEF patients treated with AIR001 showed a statistically significant decrease in pulmonary capillary wedge pressure during exercise compared to control.
    | Mon, Sep. 26, 11:38 AM | 21 Comments
  • Tue, Sep. 20, 5:14 PM
    • Mast Therapeutics (NYSEMKT:MSTX) says phase-3 EPIC trial of vepoloxamer, which treats individuals with sickle cell disease experiencing vaso-occlusive crisis, did not meet its primary efficacy endpoint.
    • Endpoint was  statistically significant reduction in the mean duration of VOC (82 hours in the vepoloxamer group compared to 78 hours in the placebo group in the intent-to-treat population (p=0.09)). There were no statistically significant differences between treatment groups in the intent-to-treat population across the two secondary efficacy endpoints, rate of re-hospitalization for VOC and the occurrence of acute chest syndrome.
    • Company: "We are exceedingly disappointed with these top-line results... These analyses are limited to just top-line data, so in the coming weeks the Company intends to review the full data set from EPIC. In addition, we plan to perform an interim analysis of the ongoing heart failure trial of vepoloxamer.
    • "However, based on the data we've seen to date, we expect we will terminate all clinical development of vepoloxamer. Consequently, while we evaluate our options, we intend to significantly and immediately reduce our operating expenses and continue our efforts with AIR001, our lead asset in heart failure with preserved ejection fraction, which currently is the subject of a 100-patient phase 2 study expected to complete enrollment by the end of 2017."
    • Conference call tomorrow, September 21, 2016, at 8:00 a.m. ET / 5:00 a.m. PT to discuss the results.
    • Shares -78% to $0.13 AH.
    | Tue, Sep. 20, 5:14 PM | 86 Comments
  • Fri, Sep. 2, 3:12 PM
    • Micro cap Mast Therapeutics (MSTX +23.7%) heads north on a 4x surge in volume. No particular news accounts for the move, but data from a Phase 3 clinical trial, EPIC, assessing lead product candidate vepoloxamer for the treatment of patients with sickle cell disease (SCD) experiencing vaso-occlusive crisis (VOC) are expected this month.
    • Investors need to be cautious here. Enrollment was completed in February and the time periods to assess efficacy endpoints were 4 - 14 days which means the company has been "analyzing" the data for six months. If the results were clearly positive, the announcement would most likely have been made promptly. According to a July letter to shareholders, CEO Brian Culley said the company was working diligently to complete the data cleaning, validation and QA/QC work required to lock and unblind the database. Mast is under additional pressure for a positive outcome because it will have to prepay $10M of the principal balance of an outstanding loan if the trial fails.
    • VOC, a painful complication of SCD, occurs when the circulation of blood vessels is obstructed by sickled red blood cells. One of the most severe forms of VOC is acute chest syndrome which occurs when blood flow to the lungs is restricted.
    • Vepoloxamer is a purified form of a copolymer called poloxamer 188, which selectively adheres to hydrophobic (water repelling) portions of cells and molecules, creating a barrier that inhibits other adhesive hydrophobic interactions. The net pharmacologic effects are improved blood flow, blood clot prevention (fibrinolysis) and reductions in inflammation and thrombosis (blood clotting). On a damaged cell, vepoloxamer restores membrane integrity and provides time for the cell's natural repair mechanisms to restore normal function.
    • Previously: Mast completes enrollment in late-stage study of vepoloxamer in sickle cell disease (Feb. 22)
    • Clarification: In March, the company stated that it expected to report top-line data in Q2. In June, it revised its forecast for the database lock to July with the data readout to follow shortly thereafter. In July, it revised the time line again to September. It attributed the delays to the "multitude of data points in the study and QC/QA procedures "taking longer than expected." [this news item was originally published on Sept. 1]
    | Fri, Sep. 2, 3:12 PM | 139 Comments
  • Tue, Aug. 9, 8:07 AM
    • Mast Therapeutics (NYSEMKT:MSTX): Q2 EPS of -$0.05 beats by $0.01.
    • Cash and equivalents of $35.07M
    • Press Release
    | Tue, Aug. 9, 8:07 AM | 3 Comments
  • Fri, May 6, 9:30 AM
    • Mast Therapeutics (MSTX) Q1 results: Revenues: $0; R&D Expense: $7.9M (+31.7%); SG&A: $2.8M (-22.2%); Operating Loss: ($10.7M) (-10.3%); Net Loss: ($11.2M) (-16.7%); Loss Per Share: ($0.06) (unch); Quick Assets: $37.1M (-9.5%).
    • No guidance given.
    | Fri, May 6, 9:30 AM | 8 Comments
  • Fri, May 6, 8:09 AM
    • Mast Therapeutics (NYSEMKT:MSTX): Q1 EPS of -$0.06 in-line.
    | Fri, May 6, 8:09 AM | 1 Comment
  • Mon, Mar. 14, 8:59 AM
    • Mast Therapeutics (MSTX) Q4 results: Revenues: $0; R&D Expense: $7.5M (+53.1%); SG&A: $2.5M (+4.2%); Operating Loss: ($9.7M) (-31.1%); Net Loss: ($10.2M) (-39.7%); Loss Per Share: ($0.06) (-20.0%).
    • FY2015 results: Revenues: $0; R&D Expense: $28.3M (+45.9%); SG&A: $11M (+15.8%); Operating Loss: ($39.4M) (-34.5%); Net Loss: ($39.8M) (-38.7%); Loss Per Share: ($0.25) (-8.7%); Quick Assets: $41M (-28.4%).
    • No guidance given.
    | Mon, Mar. 14, 8:59 AM | 1 Comment
  • Mon, Mar. 14, 8:04 AM
    • Mast Therapeutics (NYSEMKT:MSTX): Q4 EPS of -$0.06 in-line.
    | Mon, Mar. 14, 8:04 AM | 16 Comments
  • Mon, Feb. 22, 3:30 PM
    • Mast Therapeutics (MSTX +7.7%) completes enrollment of 388 subjects in a Phase 3 clinical trial, EPIC, assessing lead product candidate vepoloxamer for the treatment of patients with sickle cell disease (SCD) experiencing vaso-occlusive crisis (VOC). Top-line results should be available in Q2.
    • EPIC's primary endpoint is the reduction in duration of VOC. Secondary endpoints are rehospitalization rate for VOC and occurrence of acute chest syndrome.
    • Vepoloxamer is a purified form of a copolymer called poloxamer 188, which selectively adheres to hydrophobic (water repelling) portions of cells and molecules, creating a barrier that inhibits other adhesive hydrophobic interactions. The net pharmacologic effects are improved blood flow, blood clot prevention (fibrinolysis) and reductions in inflammation and thrombosis (blood clotting). On a damaged cell, vepoloxamer restores membrane integrity and provides time for the cell's natural repair mechanisms to restore normal function.
    • VOC, a painful complication of SCD, occurs when the circulation of blood vessels is obstructed by sickled red blood cells. One of the most severe forms of VOC is acute chest syndrome which occurs when blood flow to the lungs is restricted.
    | Mon, Feb. 22, 3:30 PM | 1 Comment
  • Wed, Feb. 10, 9:37 AM
    • Mast Therapeutics (MSTX -40.2%) prices its public offering of 29,090,910 units at $0.275 per unit. Each unit consists of one share of common stock and one five-year warrant to purchase one share of common at $0.42. Net proceeds will be ~$7.3M. Closing date is February 16.
    • Net proceeds will fund the clinical development and commercialization of vepoloxamer, working capital and general corporate purposes.
    • Previously: Mast initiates equity offering (Feb. 9)
    | Wed, Feb. 10, 9:37 AM | 3 Comments
  • Tue, Feb. 9, 4:42 PM
    • Mast Therapeutics (NYSEMKT:MSTX) commences a public offering of stock and warrants. Price, volume and terms have yet to be announced. Net proceeds will fund the clinical development and commercialization of vepoloxamer, working capital and general corporate purposes.
    | Tue, Feb. 9, 4:42 PM | 11 Comments